CVS Health is adding a senior data and technology executive from JPMorgan Chase to its board as the healthcare company expands its use of artificial intelligence and works to strengthen its financial performance. Teresa Heitsenrether, JPMorgan’s Chief Data & Analytics Officer, will join the CVS Health Board of Directors on November 18, 2026.
At the same time, Larry Robbins, CEO of Glenview Capital Management, has left the board. His departure took effect on August 13, ending a two-year tenure that began after Glenview pushed for changes in CVS’s governance and operating performance.
Who Is Joining the CVS Board?
Heitsenrether brings nearly 40 years of experience in financial services. At JPMorgan Chase, she serves as Chief Data & Analytics Officer and is a member of the firm’s Operating Committee.
Before taking that position, she held senior roles, including CEO of Securities Services and Global Head of Prime Brokerage & Equity Financing. Her experience covers data and analytics, artificial intelligence, risk management, technology transformation and complex international operations.
CVS Chair and CEO David Joyner said her background will add expertise in data, analytics, AI and operational transformation as the company continues its shift toward a consumer-focused health technology business.
Robbins Leaves After Two Years
Robbins joined CVS’s board in 2024 after Glenview Capital Management sought greater changes at the company. During his tenure, he served on the Audit Committee and the Public Policy and External Affairs Committee.
CVS credited Robbins with helping sharpen its financial and operational focus during a period of transition. Robbins said the goal of Glenview’s involvement was to improve operating performance, strengthen financial discipline and restore value for customers, employees, lenders and shareholders.
The board has changed considerably since that period. Several Glenview-backed directors joined in 2024, taking the board to 16 members. It has since been reduced to 13.
CVS Reports Stronger Second-Quarter Results
The board changes come shortly after CVS reported a stronger second quarter.
CVS recorded $106.1 billion in revenue for the three months ended June 30, up 7.3% from $98.9 billion a year earlier. GAAP diluted earnings per share increased to $2.31 from $0.80, while adjusted EPS rose to $2.58 from $1.81.
The company also generated $10.6 billion in operating cash flow during the first half of 2026.
CVS raised its full-year outlook alongside the results. It now expects GAAP diluted EPS of $6.84 to $7.04, compared with its previous forecast of $6.24 to $6.44. Adjusted EPS guidance increased to $7.90 to $8.10, while operating cash-flow guidance rose to at least $11.5 billion.
The company said the upgraded outlook reflects improved performance in its health care benefits and pharmacy & consumer wellness businesses. It nevertheless warned that elevated medical-cost trends and possible macroeconomic pressures remain concerns.
AI Is Becoming a Larger Part of CVS’s Business
The appointment of a senior data executive comes as CVS expands its technology strategy.
In March, CVS and Google Cloud announced a strategic partnership around Health100, a health technology subsidiary designed to create a connected digital experience for consumers. The platform is being developed using Google Cloud technologies, including Gemini models, Cloud Healthcare API, and BigQuery.
CVS said Health100 is intended to help consumers manage their care, receive proactive support, compare costs, and connect with health-care services. The company also plans to use the platform to connect consumers with pharmacist-led care management.
Beyond the consumer platform, CVS has been applying AI to operational processes, including claims and medication-related workflows. The company has also expanded internal AI training as it develops technology capabilities across its workforce.
Medicare Advantage Remains a Key Challenge
Technology investment is happening alongside changes to CVS’s insurance business.
Aetna had approximately 4.1 million Medicare Advantage members in 2026. The company reduced enrollment by about 130,000 members and narrowed its market footprint as it focused more heavily on profitability and medical-cost management rather than pursuing membership growth at any cost.
Despite the smaller membership base, more than 81% of Aetna’s Medicare Advantage members were enrolled in plans rated four stars or higher for 2026.
The adjustments reflect the pressure insurers face from rising medical costs and the need to balance membership growth with sustainable plan economics.
What the Board Change Signals for CVS
Heitsenrether’s appointment adds financial services and technology experience at a time when CVS is trying to connect its insurance, pharmacy, care delivery, and digital operations more closely.
Her background does not indicate that CVS has announced a new acquisition or specific AI initiative tied to the appointment. Instead, the change gives the board additional expertise in areas that are already central to the company’s stated strategy.
Robbins’ exit, meanwhile, marks a transition from the governance changes that followed Glenview’s involvement in 2024. CVS now enters the next phase with stronger recent financial results, higher 2026 guidance, and a growing technology agenda, while continuing to manage medical-cost pressure in its insurance business.
Bottom Line
CVS Health is bringing JPMorgan Chase data chief Teresa Heitsenrether onto its board as the company expands its technology strategy and reports improved 2026 financial performance. Her appointment will take effect November 18.
Larry Robbins’ departure closes his two-year board tenure after Glenview pushed for operational and governance changes at CVS. The company now faces the task of sustaining its financial recovery while executing its AI and digital-health plans across a business that includes Aetna, Caremark, pharmacies, and health-care services.
FAQs
Who is joining the CVS Health board?
Teresa Heitsenrether, JPMorgan Chase’s Chief Data & Analytics Officer, is joining the CVS Health Board of Directors.
When will Teresa Heitsenrether join the CVS Health board?
Her appointment is scheduled to take effect on November 18, 2026.
Why is Teresa Heitsenrether joining CVS Health’s board?
Heitsenrether brings experience in data and analytics, artificial intelligence, technology transformation, risk management and financial services, areas that align with CVS Health’s expanding digital and AI strategy.
Who is leaving the CVS Health board?
Larry Robbins, CEO of Glenview Capital Management, left the CVS Health board effective August 13, 2026.
How long was Larry Robbins on the CVS Health board?
Robbins served on the board for about two years, having joined in 2024 following Glenview Capital Management’s push for governance and operational changes at CVS.
What was CVS Health’s revenue in the second quarter of 2026?
CVS Health reported $106.1 billion in revenue for the quarter ended June 30, 2026, up 7.3% from $98.9 billion a year earlier.
Did CVS Health raise its 2026 financial outlook?
Yes. CVS raised its full-year guidance, including adjusted EPS to $7.90–$8.10 and operating cash-flow guidance to at least $11.5 billion.
How is CVS Health using artificial intelligence?
CVS is expanding AI and data capabilities across areas including its Health100 digital-health platform, claims processes and medication-related workflows. The company is also using Google Cloud technologies as part of its Health100 strategy.
What is Health100?
Health100 is a CVS Health health-technology initiative designed to create a more connected digital experience for consumers, including tools for managing care, comparing costs and connecting with health-care services.
What challenges does CVS Health face in its insurance business?
CVS continues to manage higher medical-cost trends and pressure on Medicare Advantage profitability, while trying to balance membership, plan economics and long-term financial performance.
